This pattern, affecting immune responses like IFN-γ and IFN-α, was consistent across various patient cohorts, reinforcing the notion that PBRM1 mutations on the immune dynamics of RCC and its responsiveness to immunotherapy.95 These mutations not only disrupt crucial immune signaling pathways but also alter the tumor’s immune environment, influencing the tumor’s response to immunotherapy. The gene discussed is IFNG; the disease is neoplasm.